JAMA

The Aging Revolution: Growing old in America becoming more dignified, but with senior population booming, is nation’s health system prepared?

Retrieved on: 
Dienstag, Juni 4, 2024

The apathy often resulted in inferior care for aging adults who frequently struggled with multiple chronic conditions that were largely ignored by physicians, who saw pain and suffering as inevitable to the aging process.

Key Points: 
  • The apathy often resulted in inferior care for aging adults who frequently struggled with multiple chronic conditions that were largely ignored by physicians, who saw pain and suffering as inevitable to the aging process.
  • The book, published by Skyhorse Publishing , analyzes the social action movements since the 1970s that have dramatically improved the quality of life and life expectancy of adults.
  • The emergence and expansion of palliative care programs to manage patients’ pain and improve quality of life, a specialized medical practice that has spread to nearly every US health system.
  • New initiatives that train, partially compensate and support millions of family caregivers tending to loved ones in the home.

Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA

Retrieved on: 
Samstag, Juni 1, 2024

This is a clinical setting with a patient population where PD-1 monoclonal antibodies have previously been unsuccessful in Phase III global clinical trials.

Key Points: 
  • This is a clinical setting with a patient population where PD-1 monoclonal antibodies have previously been unsuccessful in Phase III global clinical trials.
  • The Phase III HARMONi-A study provides further evidence supporting the differentiated mechanism of action of ivonescimab, a PD-1 / VEGF bispecific antibody evidencing cooperative binding characteristics.
  • Summit Therapeutics Inc. will host a conference call to discuss recent updates related to ivonescimab, including data released at ASCO, on Monday, June 3, 2024, before the market opens.
  • An archived edition of the webcast will be available on our website later in the day on Monday.

HEALWELL AI’s Pentavere Partners with Sunnybrook and Successfully Demonstrates its AI Powered Clinician Co-pilot System Can Improve Cancer Staging in Prestigious Peer-Reviewed Medical Journal

Retrieved on: 
Dienstag, Mai 21, 2024

Pentavere partnered with Sunnybrook Health Sciences Centre to demonstrate how Pentavere’s DARWEN™ AI platform can help enhance cancer staging to improve patient outcomes.

Key Points: 
  • Pentavere partnered with Sunnybrook Health Sciences Centre to demonstrate how Pentavere’s DARWEN™ AI platform can help enhance cancer staging to improve patient outcomes.
  • This work underscores the potential of AI in enhancing patient care and oncological decision-making and demonstrates the potential impact of AI powered clinical decision support as a Co-pilot to physicians to improve cancer patient outcomes.
  • The results highlighted in the JAMA paper found AI has the potential to enhance patient care and oncological decision-making.
  • DARWEN™, Pentavere’s AI platform, unlocks a deeper understanding of patient treatment needs by enabling effortless data access and rapid insight generation.

Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress

Retrieved on: 
Donnerstag, Mai 16, 2024

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the first quarter ended March 31, 2024 and reviewed recent business highlights.

Key Points: 
  • Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the first quarter ended March 31, 2024 and reviewed recent business highlights.
  • Collaboration Revenue: Collaboration revenue was £12.4 million, an increase of £1.0 million compared with the first quarter of 2023.
  • R&D Expenses: Research and development (R&D) expenses were £9.2 million, a decrease of £3.4 million compared to the first quarter of 2023.
  • G&A Expenses: General and administrative (G&A) expenses were £5.2 million, a decrease of £1.3 million compared to the first quarter of 2023.

Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update

Retrieved on: 
Donnerstag, Mai 9, 2024

Achieve expects to conduct an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in 2024 to discuss future plans for an expanded label in e-cigarette cessation.

Key Points: 
  • Achieve expects to conduct an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in 2024 to discuss future plans for an expanded label in e-cigarette cessation.
  • Total operating expenses for the first quarter ended March 31, 2024 were $6.0 million.
  • The total net loss for the first quarter ended March 31, 2024 was $6.5 million.
  • Achieve will host a conference call at 4:30 PM EDT today, Thursday, May 9, 2024.

Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine

Retrieved on: 
Montag, Mai 6, 2024

SEATTLE and VANCOUVER, British Columbia, May 06, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced publication of the ORCA-V1 trial results in the Journal of the American Medical Association (JAMA) Internal Medicine. ORCA-V1 evaluated the efficacy and safety of 3 mg cytisinicline dosed three times daily for 12 weeks compared to placebo in 160 non-smoking adults who used e-cigarettes or nicotine vapes and wanted to quit e-cigarettes. All participants received behavioral support for vaping cessation.

Key Points: 
  • SEATTLE and VANCOUVER, British Columbia, May 06, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced publication of the ORCA-V1 trial results in the Journal of the American Medical Association (JAMA) Internal Medicine .
  • As reported today, the ORCA-V1 trial demonstrated that biochemically confirmed continuous vaping abstinence during the last 4 weeks of treatment, the primary outcome measure, was significantly higher for cytisinicline treatment compared to placebo.
  • During the 12-week study treatment, the past seven-day prevalence of vaping abstinence at each week was consistently higher in the cytisinicline group than the placebo group.
  • Achieve plans to conduct an End-of-Phase 2 Meeting with the FDA later this year to discuss future clinical trial requirements to pursue an indication for vaping cessation.

Feinstein Institutes study challenges the use of thick liquid diets in hospitalized patients with dementia and dysphagia

Retrieved on: 
Montag, Mai 6, 2024

Although dysphagia diets, consisting of thick liquids, are widely used, it is unknown whether thick liquids improve patient outcomes.

Key Points: 
  • Although dysphagia diets, consisting of thick liquids, are widely used, it is unknown whether thick liquids improve patient outcomes.
  • Contrary to expectations, the study found no significant difference in hospital mortality between patients receiving thick and thin liquids.
  • This primary outcome raises important questions about the benefits of thick liquids for dysphagia management in hospitalized patients with ADRD.
  • These studies should integrate instrumental assessments such as Modified Barium Swallow Studies (MBSS) to assess the influence of thick liquids on clinical outcomes in hospitalized patients with ADRD and dysphagia.

New PRI Brief: JAMA Study Justifying Drug Price Controls Deeply Flawed, Patient Health Jeopardized if Findings Implemented

Retrieved on: 
Mittwoch, Mai 8, 2024

To justify price controls, Sanders cites the JAMA study ("Estimated Sustainable Cost-Based Prices for Diabetes Medicines" by Barber, Gotham and Bygrave) claiming innovative diabetes medicines can be manufactured for $5 a month.

Key Points: 
  • To justify price controls, Sanders cites the JAMA study ("Estimated Sustainable Cost-Based Prices for Diabetes Medicines" by Barber, Gotham and Bygrave) claiming innovative diabetes medicines can be manufactured for $5 a month.
  • Winegarden and Pipes identify numerous flaws that invalidate the study's results and highlight how the Sanders agenda would put patient health at risk.
  • In one identified flaw, the JAMA authors do not adequately define excessive profits, despite it being their study's central premise.
  • Winegarden and Pipes argue the authors would consider recouping drug innovation costs in setting prices to be "excessive."

Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab

Retrieved on: 
Donnerstag, April 25, 2024

Toripalimab plus chemotherapy also reduced the risk of disease progression or death by 48% and the risk of death by 37%, all while demonstrating a manageable safety profile.

Key Points: 
  • Toripalimab plus chemotherapy also reduced the risk of disease progression or death by 48% and the risk of death by 37%, all while demonstrating a manageable safety profile.
  • So far, toripalimab has been approved for marketing in the Chinese mainland and the US.
  • Several NDAs are currently under regulatory review in the European Union, UK, Australia, Singapore, Malaysia and Hong Kong Special Administrative Region (“SAR”).
  • Furthermore, NDAs for toripalimab have also been submitted in India, South Africa, Chile and Jordan.

Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immunology Expert, as Executive Vice President and Head of Research and Development, and Strengthens Scientific Advisory Board with the Addition of Dr. Adrian

Retrieved on: 
Dienstag, April 23, 2024

“We are thrilled to welcome Ajay and Adrian to Recludix,” said Nancy Whiting, PharmD, CEO of Recludix. “Ajay joins us from Eli Lilly with over two decades of executive leadership experience spanning all stages of drug discovery and development. He has extensive expertise in immunology and has led the advancement and strategic oversight of deep pipelines with more than ten product candidates reaching the clinic during his Lilly tenure. At Recludix, we have a robust pipeline of validated targets, starting with our two lead programs -- oral and reversible inhibitors of STAT3 and STAT6. Additionally, our proprietary drug discovery platform has enabled us to drug many other exciting previously undruggable SH2 domain targets. Ajay’s deep experience leading a broad discovery and development immunology portfolio – both internally and through strategic partnerships -- is ideally suited to capitalize on the many opportunities at Recludix.”

Key Points: 
  • “We are thrilled to welcome Ajay and Adrian to Recludix,” said Nancy Whiting, PharmD, CEO of Recludix.
  • “Ajay joins us from Eli Lilly with over two decades of executive leadership experience spanning all stages of drug discovery and development.
  • At Recludix, we have a robust pipeline of validated targets, starting with our two lead programs -- oral and reversible inhibitors of STAT3 and STAT6.
  • Additionally, our proprietary drug discovery platform has enabled us to drug many other exciting previously undruggable SH2 domain targets.